Reich, K., Simpson, E., Langley, R., Warren, R., Costanzo, A. ., Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., De Bruin Weller, M. and Blauvelt, A. (2023) “Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest”, SKIN The Journal of Cutaneous Medicine, 7(2), p. s143. doi: 10.25251/skin.7.supp.143.